Act in the present, prepare for the future


Supported a project led by Dr Thomas Matthes to improve the diagnosis and treatment of leukaemia

Many different types of leukaemia can now be identified by analysing their genome. The molecular diagnostics platform developed by the haematology team at the Geneva University Hospitals is the only one of its kind in Switzerland. In under a week, it can identify the best treatment for a given patient based on the abnormalities detected in the genome of his or her leukaemia cells. This applied research will eventually enable the team to identify all the “false notes” in a diseased cell and develop a type of barcode, which will allow doctors to select the most effective treatments and avoid ineffectual or potentially toxic ones.


Renewed funding for the fetoplacental blood bank at Geneva University Hospitals.


Provided funding for the fetoplacental blood bank for medullary transplants at Geneva University Hospitals

For many leukaemia sufferers, a bone marrow transplant offers the only chance of recovery. Marrow can be provided by a family member or an unrelated donor. However, despite a pool of 20 million potential donors, about 30% of patients die before a match can be found. Cord blood, also known as fetoplacental blood, offers a solution to this problem. Like bone marrow, it contains haematopoietic (blood) stem cells. It can be easily collected with a syringe from the umbilical cord of newborns. The stem cells can be stored and later used as medullary transplants for leukaemia patients. To ensure the success of this process, which the Foundation has chosen to support, a number of steps are necessary: pregnant women need to be informed about the process and the importance of anonymous donation, medical personnel motivated, the stem cells stored, the data entered into an international database, the right choices made for each patient, and the stem cells sterilised before transplantation.


Provided funding for the project “Towards a molecular classification of leukaemias”, which aims to diagnose acute leukaemias more quickly and precisely in order to increase patients’ chances of survival.


Inauguration of the Dr Henri Dubois-Ferrière Dinu Lipatti Foundation Clinical Research Unit
This research unit is the result of a successful partnership between a private non-profit, the DFDL Foundation, and a large public institution, the Geneva University Hospitals. For statutory reasons, the foundation funded the purchase of equipment and the Geneva University Hospitals funded structural work.


Pledged 1 million Swiss francs per year for five years for the Centre for Onco-Haematology Research, Department of Oncology.


Inauguration of the Bone Marrow Transplantation Unit on 30 January 2007.


Partnered with BNP Paribas Foundation to support successful research that aimed to assess patients’ vulnerability to viral infection after transplantation.
Contributed to the modernisation of several medical units in partnership with the Geneva University Hospitals.

2004 – 2005

Co-funded the renovation of the Blood Transfusion Centre at the Geneva University Hospitals.


Soutien à trois groupes de recherche en thérapies cellulaires.


Supported a study entitled “Immune deficiencies after haematopoietic progenitor cell transplantation” (bone marrow graft). The principal author was awarded the highly coveted “Robert Wenner Prize” by the Swiss Cancer League.


Helped create a research unit dedicated to identifying genetic predispositions to cancer.

1989 – 1997

Co-funded the modernisation of the Paediatric Onco-Haematology unit at the Geneva University Hospitals. More specifically, the foundation supported the creation of a sterile area for children undergoing treatment for acute leukaemia and other severe forms of cancer.


Funded the purchase of sterile laminar flow systems used in isolation systems for transplant patients.